Avanza Fonder AB Has $5.57 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avanza Fonder AB cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,899 shares of the biopharmaceutical company's stock after selling 1,509 shares during the period. Avanza Fonder AB's holdings in Regeneron Pharmaceuticals were worth $5,567,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $25,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $32,000. Finally, Curat Global LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $4.93 during trading hours on Wednesday, reaching $518.60. 961,902 shares of the company were exchanged, compared to its average volume of 873,023. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $565.85 and a 200 day moving average of $654.03. The firm has a market cap of $55.99 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the business earned $9.55 EPS. The business's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a report on Monday, June 2nd. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. Bank of America dropped their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.